Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.70 to $2.85
• 50-Day Range: $2.37 to $5.32
• 52-Week Range: $1.27 to $9.47
• Volume: 3,549 shs
• Average Volume: 1.32 million shs
• Market Capitalization: $7.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed this year?

Cyclerion Therapeutics' stock was trading at $3.22 on January 1st, 2025. Since then, CYCN stock has decreased by 14.6% and is now trading at $2.75.
View the best growth stocks for 2025 here.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, March, 4th. The company reported $0.22 EPS for the quarter. The business earned $1.81 million during the quarter.

When did Cyclerion Therapeutics' stock split?

Cyclerion Therapeutics shares reverse split on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Cyclerion Therapeutics' major shareholders?

Top institutional shareholders of Cyclerion Therapeutics include Renaissance Technologies LLC (0.39%) and Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/04/2025
• Today: 3/23/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCN
• CIK: 1755237
• Web: www.cyclerion.com
• Phone: (857) 327-8778
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,260,000.00
• Net Margins: N/A
• Pretax Margin: -2,722.68%
• Return on Equity: -55.32%
• Return on Assets: -48.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.07
• Quick Ratio: 5.07

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 3.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.62 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 2,710,000
• Free Float: 1,732,000
• Market Cap: $7.45 million
• Optionable: No Data
• Beta: 2.09